Alps Advisors Inc Capricor Therapeutics, Inc. Transaction History
Alps Advisors Inc
- $17.2 Billion
- Q2 2025
A detailed history of Alps Advisors Inc transactions in Capricor Therapeutics, Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 24,671 shares of CAPR stock, worth $158,634. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,671
Previous 33,230
25.76%
Holding current value
$158,634
Previous $315,000
22.54%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CAPR
# of Institutions
140Shares Held
12.3MCall Options Held
4.99MPut Options Held
5.52M-
Vanguard Group Inc Valley Forge, PA2.31MShares$14.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.63MShares$10.5 Million0.0% of portfolio
-
State Street Corp Boston, MA1.47MShares$9.43 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA963KShares$6.19 Million0.0% of portfolio
-
Morgan Stanley New York, NY551KShares$3.54 Million0.0% of portfolio
About CAPRICOR THERAPEUTICS, INC.
- Ticker CAPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,346,200
- Market Cap $157M
- Description
- Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...